VIRACTA THERAPEUTICS INC has a total of 19 patent applications. It decreased the IP activity by 90.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are FORTE SUBSIDIARY INC, LAMELLAR BIOMEDICAL LTD and ERICKSON-MILLER CONNIE.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | China | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | United Kingdom | 2 | |
#6 | Uruguay | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Woody James N | 8 |
#2 | Warren Marshelle | 5 |
#3 | Trauger Richard | 4 |
#4 | Mcrae Robert | 4 |
#5 | Daniels Preston | 4 |
#6 | Soon-Shiong Patrick | 4 |
#7 | Slack David | 4 |
#8 | Deng Xiaohu | 3 |
#9 | Brown Gail L | 2 |
#10 | James N Woody | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021071809A1 | Dosages for hdac treatment with reduced side effects | |
US2020375990A1 | Methods of treating virally associated cancers with histone deacetylase inhibitors | |
UY38720A | METHODS FOR TREATING VIRUS-ASSOCIATED CANCERS WITH HISTONE DEACETILASE INHIBITORS | |
EP3737405A1 | Epigenetic modifiers for use in cellular immunotherapy | |
CN109803661A | Histone deacetylase inhibitor for immunotherapy |